戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 erlies neurodegenerative diseases, including Alzheimer's.
2  for enhanced stability and affinity for the Alzheimer's Abeta42 peptide.
3 s with neurodegenerative diseases, including Alzheimer's and Parkinson's disease, are thought to spre
4 ed to immune-to-brain communication, such as Alzheimer's and Parkinson's diseases.
5 nd to common neurodegenerative diseases like Alzheimer's and Parkinson's.
6  designed immunotherapy strategies to combat Alzheimer's and related neurodegenerative diseases.
7 differentiating between clinically diagnosed Alzheimer's and subcortical vascular cognitive impairmen
8  according to US National Institute on Aging-Alzheimer's Association neuropathological criteria, and
9 microglial proliferation in a mouse model of Alzheimer's beta-amyloidosis was increased threefold.
10 ired helical filament (PHF)-tau pathology in Alzheimer's brains.
11 h their associations with amyloid plaques in Alzheimer's brains: RTN3, but not RTN1, is abundantly en
12 tudy eligibility criteria, from the National Alzheimer's Coordinating Center (NACC) (n = 5,073, 158 A
13 or restoring cognitive function in aging and Alzheimer's dementia.
14  treatment may delay progression from MCI to Alzheimer's dementia.
15 ught to play an essential pathogenic role in Alzheimer s disease (AD).
16 d be categorised as stage 2 or 3 preclinical Alzheimer's disease (A+T+N-, A+T-N+, and A+T+N+; 86% at
17 STATEMENT Understanding how risk factors for Alzheimer's disease (AD) affect brain function and cogni
18 bustly accumulate within axonal swellings at Alzheimer's disease (AD) amyloid plaques.
19                       Tauopathies, including Alzheimer's disease (AD) and other neurodegenerative con
20 nosis of neurodegenerative disorders such as Alzheimer's disease (AD) and related Dementias has been
21 ant post-translational modification (PTM) in Alzheimer's disease (AD) and related tauopathies.
22 l destruction methods.SIGNIFICANCE STATEMENT Alzheimer's disease (AD) and similar dementias are commo
23 ingulate cortex (PCC) predicts conversion to Alzheimer's disease (AD) and tracks disease progression,
24                       The earliest stages of Alzheimer's disease (AD) are characterized by the format
25            The drugs currently used to treat Alzheimer's disease (AD) are limited in the benefits the
26                                Most cases of Alzheimer's disease (AD) are sporadic, but a small perce
27 splant (KT) may develop post-KT dementia and Alzheimer's disease (AD) associated with their long-stan
28 laques, a potential biomarker present in the Alzheimer's disease (AD) brain is crucial for both clini
29 a-amyloid (Abeta) plaques are key lesions in Alzheimer's disease (AD) but both pathologies also occur
30 pse degeneration and cognitive impairment in Alzheimer's disease (AD) by reactivating expression of t
31    A genome-wide survival analysis of 14,406 Alzheimer's disease (AD) cases and 25,849 controls ident
32  proteinopathy patients while accounting for Alzheimer's disease (AD) copathology.
33 nterest on Tau protein is fast increasing in Alzheimer's disease (AD) diagnosis.
34 lot study on differentiating early stages of Alzheimer's disease (AD) from Dementia with Lewy Bodies
35        Many models of disease progression in Alzheimer's disease (AD) have been proposed to help guid
36                    Pathological hallmarks of Alzheimer's disease (AD) include amyloid-beta (Abeta) pl
37                                              Alzheimer's disease (AD) is a detrimental neurodegenerat
38                      SIGNIFICANCE STATEMENT: Alzheimer's disease (AD) is a devastating neurodegenerat
39                                              Alzheimer's disease (AD) is a prevalent neurodegenerativ
40                                              Alzheimer's disease (AD) is a type of dementia that caus
41                 The pathological hallmark of Alzheimer's disease (AD) is accumulation of misfolded am
42                  Elevated risk of developing Alzheimer's disease (AD) is associated with hypomorphic
43                                              Alzheimer's disease (AD) is characterized by deposition
44                                              Alzheimer's disease (AD) is characterized by extracellul
45                                              Alzheimer's disease (AD) is characterized by progressive
46                                              Alzheimer's disease (AD) is characterized by severe neur
47                                              Alzheimer's disease (AD) is characterized by the presenc
48 ein E-epsilon4 carriers, is a major risk for Alzheimer's disease (AD) is increasing steadily, with ov
49                   A key molecular species in Alzheimer's disease (AD) is the Abeta42 alloform of Abet
50                                              Alzheimer's disease (AD) is the most common form of deme
51  current frontline symptomatic treatment for Alzheimer's disease (AD) is whole-body upregulation of c
52 y-Camacho et al. (2017) generate a humanized Alzheimer's disease (AD) model that reveals species-spec
53  FASS-LTP analysis in two well-characterized Alzheimer's disease (AD) mouse models (3xTg and Tg2576)
54 oinflammation is an important contributor to Alzheimer's disease (AD) pathogenesis, as underscored by
55  inflammation can play a significant role in Alzheimer's disease (AD) pathogenesis.
56 ilable on the effect of canola oil intake on Alzheimer's disease (AD) pathogenesis.
57 P) has long been appreciated for its role in Alzheimer's disease (AD) pathology.
58 igomeric amyloid-beta (Abetao) in triggering Alzheimer's disease (AD) pathophysiology.
59 emale CRF-OE mice were overrepresented in an Alzheimer's disease (AD) pathway.
60 protein (oAbeta) isolated from the brains of Alzheimer's disease (AD) patients have been shown experi
61 ormin 2 (Fmn2) is deregulated in PTSD and in Alzheimer's disease (AD) patients.
62  in addition to local brain inflammation, in Alzheimer's disease (AD) progression.
63 al, and symptomatic heterogeneity underlying Alzheimer's disease (AD) requires a deep understanding o
64                        Early intervention in Alzheimer's Disease (AD) requires novel biomarkers that
65 eference region differences between SVaD and Alzheimer's disease (AD) using Centiloid scores.
66 myloid-beta pathology early in the course of Alzheimer's disease (AD) with high sensitivity and speci
67  with frontotemporal dementia (FTD-ALS), and Alzheimer's disease (AD), and found profound apical dend
68 s upregulated in the brains of patients with Alzheimer's disease (AD), and its expression levels infl
69 ques are a key histopathological hallmark of Alzheimer's disease (AD), and soluble Abeta species are
70 s the most important genetic risk factor for Alzheimer's disease (AD), ApoE3 is neutral, and ApoE2 is
71 gate the effect of a genetic risk factor for Alzheimer's disease (AD), ApolipoproteinE epsilon4 (APOE
72         Serious brain disorders, such as the Alzheimer's Disease (AD), are associated with a marked d
73 at the intermediate and late Braak stages of Alzheimer's disease (AD), as well as in other neurodegen
74 eta) plays a key role in the pathogenesis of Alzheimer's disease (AD), but little is known about the
75 ne loss is recognized as an early feature of Alzheimer's disease (AD), but the underlying mechanisms
76 gomers is one of the earliest impairments in Alzheimer's Disease (AD), driving initial cognitive defi
77 of tau proteins, termed tauopathies, include Alzheimer's disease (AD), frontotemporal lobar degenerat
78      While SMD might be the earliest sign of Alzheimer's disease (AD), it also occurs in aging and va
79 been the central dogma in drug discovery for Alzheimer's disease (AD), leading to many small-molecule
80 rophy in seven neurodegenerative conditions (Alzheimer's disease (AD), Parkinson's disease (PD) and H
81                                              Alzheimer's disease (AD), via frontal compensatory proce
82 Age is, by far, the greatest risk factor for Alzheimer's disease (AD), yet few AD drug candidates hav
83                                              Alzheimer's disease (AD)-linked mutations in Presenilins
84 s in Amytrophic Lateral Sclerosis (ALS)- and Alzheimer's disease (AD)-linked neurons.
85 rils begin to accumulate in individuals with Alzheimer's disease (AD).
86 heir function in neurological diseases, like Alzheimer's disease (AD).
87 ansmission that is thought to be affected in Alzheimer's disease (AD).
88 iating the amyloid-beta and tau pathology in Alzheimer's disease (AD).
89  (CSF) and their potential as biomarkers for Alzheimer's disease (AD).
90 y for patients suffering from memory loss or Alzheimer's disease (AD).
91  in tauopathies, the most common of which is Alzheimer's disease (AD).
92 ate a cascade of neurodegenerative events in Alzheimer's disease (AD).
93 factors for cognitive decline and late onset Alzheimer's disease (AD).
94 as early detectable peripheral biomarkers in Alzheimer's disease (AD).
95 siderable contribution to risk of developing Alzheimer's disease (AD).
96 elates with reduced onset and progression of Alzheimer's disease (AD).
97 terations associated with the development of Alzheimer's disease (AD).
98 f the possible markers for the prediction of Alzheimer's disease (AD).
99 nephrine to the forebrain and degenerates in Alzheimer's disease (AD).
100 amma-secretase underlies the pathogenesis of Alzheimer's disease (AD).
101 mal network (ELN) are a signature feature of Alzheimer's disease (AD).
102 tion, and neurodegenerative diseases such as Alzheimer's disease (AD).
103 d to the pathologic and clinical features of Alzheimer's disease (AD).
104  in tauopathies, the most common of which is Alzheimer's disease (AD).
105 maintain cognitive function in patients with Alzheimer's disease (AD).
106 beta peptide (Abeta42) is a pivotal event in Alzheimer's disease (AD).
107 is considered central to the pathogenesis of Alzheimer's disease (AD).
108 is an initiating step in the pathogenesis of Alzheimer's disease (AD).
109 ) in fresh brain samples of a mouse model of Alzheimer's disease (AD).
110 ology of neurodegenerative disorders such as Alzheimer's disease (AD).
111 roglia is known to play an important role in Alzheimer's disease (AD).
112  nervous system-related pathologies, such as Alzheimer's disease (AD).
113 rogress in unraveling the pathophysiology of Alzheimer's disease (AD).
114 ippocampal area of patients with early-stage Alzheimer's disease (AD).
115 sent the two major pathological hallmarks of Alzheimer's disease (AD).
116                                              Alzheimer's disease (AD; n = 164) was identified with 70
117 d the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) battery (Word List Learning,
118 contributing mechanism underlying late-onset Alzheimer's disease (LOAD).
119  are also associated with increased risk for Alzheimer's disease (rg=-0.155).
120 d with aging and many human diseases such as Alzheimer's disease [1-3].
121 Cog]) and self-reported QoL (Quality of Life Alzheimer's Disease [QoL-AD]) for the person with dement
122 ociated with type 2 diabetes (T2D), with the Alzheimer's disease amyloid-beta (Abeta) peptide modulat
123 onstitute the histopathological hallmarks of Alzheimer's disease and are prominent targets for novel
124 ed the relationship between genetic risk for Alzheimer's disease and cortical thickness, such that in
125 e more clearly detected by PBB3 in brains of Alzheimer's disease and diffuse neurofibrillary tangles
126 ementia with Lewy bodies, five patients with Alzheimer's disease and five healthy control subjects to
127 to investigate pathological states including Alzheimer's disease and HIV-associated neurocognitive di
128 participants, but not those of patients with Alzheimer's disease and MCI, possess effective phagocyto
129    The innate immune system of patients with Alzheimer's disease and mild cognitive impairment (MCI)
130                         Prion diseases, like Alzheimer's disease and Parkinson disease, are rapidly p
131 unction ranging from severe loss, as seen in Alzheimer's disease and Parkinson's disease, to relative
132 ens for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
133 eases associated with hippocampal pathology (Alzheimer's disease and schizophrenia) are more enriched
134 s, including addiction, Parkinson's disease, Alzheimer's disease and schizophrenia.
135 Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychos
136            Tau-mediated neurodegeneration in Alzheimer's disease and tauopathies is generally assumed
137              However, rare forms of familial Alzheimer's disease are associated with mutations in APP
138 e decline (greater impairment on the 11-item Alzheimer's Disease Assessment Scale cognitive subscale
139             Primary outcomes were cognition (Alzheimer's Disease Assessment Scale-cognitive [ADAS-Cog
140 ipants who received IVIG performed better on Alzheimer's Disease Assessment Scale-cognitive subscale
141 ssessed by Mini-Mental State Examination and Alzheimer's Disease Assessment Scale.
142 ect of sleep modulates amyloid-beta or other Alzheimer's disease biomarkers.
143 relevance not only to the pathophysiology of Alzheimer's disease but also diet-associated obesity.
144 ll function is implicated in the etiology of Alzheimer's disease by human genetics.
145  polyneuropathy, and Abeta42 associated with Alzheimer's disease by stabilizing their respective prot
146 ocortical, limbic and subcortical areas from Alzheimer's disease cases (n = 19), neurologically norma
147 dividuals with mild cognitive impairment and Alzheimer's disease clinical diagnoses can display signi
148      We applied this tool to the analysis of Alzheimer's disease data from three datasets CHS, FHS an
149 re achieved at very low amisulpride doses in Alzheimer's disease due to higher than anticipated occup
150 o be actively involved in the development of Alzheimer's disease due to its ability to seed the aggre
151 ion and the role of environmental factors in Alzheimer's disease etiology.
152 8F-AV-1451) associated with well-established Alzheimer's disease factors in a cohort including cognit
153 duals (5,728 AD, 5,653 CN controls) from the Alzheimer's Disease Genetics Consortium (ADGC), a Nation
154 and 9,386 older controls from Phase 1 of the Alzheimer's Disease Genetics Consortium (ADGC), providin
155 ols (age at examination, >65 years) from the Alzheimer's Disease Genetics Consortium.
156 ntified rare coding variants associated with Alzheimer's disease in a three-stage case-control study
157 tor for frontotemporal dementia spectrum and Alzheimer's disease in an initial case-control study.
158 on of induced neuron-based model of sporadic Alzheimer's disease in mice and humans, and used this sy
159 l features of neurodegeneration occurring in Alzheimer's disease including age-dependent cortical atr
160                         Memory impairment in Alzheimer's disease is a manifestation of brain patholog
161 tion of AbetaOs in AD.SIGNIFICANCE STATEMENT Alzheimer's disease is characterized by progressive cogn
162                                              Alzheimer's disease is characterized by the self-assembl
163                                              Alzheimer's disease is one of the most devastating neuro
164   One of the main research topics related to Alzheimer's disease is the aggregation of the amyloid-be
165 on as seen in neurological disorders such as Alzheimer's disease may contribute to neurovascular dysf
166 ed loss of synapses and cognitive decline in Alzheimer's disease mice.
167 th mitochondrial dysfunction in the brain of Alzheimer's disease mouse model CRND8 as early as 3 mont
168 nd improved cognitive function in a familial Alzheimer's disease mouse model.
169                       External validation in Alzheimer's Disease Neuroimaging Initiative 2 showed tha
170 , and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initiative.
171 ease neuropathology, 56 (26%) with low-level Alzheimer's disease neuropathology, 45 (21%) with interm
172 thy, we identified 49 (23%) patients with no Alzheimer's disease neuropathology, 56 (26%) with low-le
173 opathology, 45 (21%) with intermediate-level Alzheimer's disease neuropathology, and 63 (30%) with hi
174 neuropathology, and 63 (30%) with high-level Alzheimer's disease neuropathology.
175  including cognitive decline associated with Alzheimer's disease or schizophrenia.
176 al in groups with varying levels of comorbid Alzheimer's disease pathology according to US National I
177 's component features.SIGNIFICANCE STATEMENT Alzheimer's disease pathology appears earliest in brain
178 ociated with dementia that is independent of Alzheimer's disease pathology or larger infarcts (ie, la
179 e in late-life depression is associated with Alzheimer's disease pathology.
180  inhibits glutamatergic synaptic function in Alzheimer's disease patients.
181 ure in vivo may correlate with variations in Alzheimer's disease phenotype, in analogy to distinct pr
182  dysfunction may be a critical early step in Alzheimer's disease progression.
183 genic mechanisms resulting from the sporadic Alzheimer's disease risk factor apolipoprotein E (APOE)
184 ction between APOE varepsilon3/4 and another Alzheimer's disease risk factor, desmoglein 2 (DSG2).
185 stributions of autoradiographic labelling of Alzheimer's disease slices with 11C-PBB3 and 18F-AV-1451
186 athology and cognitive impairment across the Alzheimer's disease spectrum.
187 icroglial activation was increased by 36% in Alzheimer's disease subjects compared with controls.
188  activation in mild cognitive impairment and Alzheimer's disease subjects.
189         Moreover, studies in mouse models of Alzheimer's disease suggest that certain classes of AEDs
190     Of particular interest, the ATP7B(K832R) Alzheimer's disease susceptibility allele was found, for
191 alterations in mild cognitive impairment and Alzheimer's disease that can complement existing dimensi
192 ent a previously unrecognized contributor to Alzheimer's disease that is independent of neuronal hypo
193 d beta precursor protein), a major player in Alzheimer's disease that is known to have immune and inf
194                                           In Alzheimer's disease the amyloid-beta peptide (Abeta) mis
195 he Abeta peptides, which are associated with Alzheimer's disease through their presence in amyloid pl
196 HOD: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's
197  existing dimensional approaches for staging Alzheimer's disease using a variety of biomarkers, which
198 s toxicity of amyloid-beta species linked to Alzheimer's disease was initially treated with scepticis
199                                              Alzheimer's disease was uncommon (6%) among patients who
200 oteins related to amyloid-beta metabolism or Alzheimer's disease were quantified by enzyme-linked imm
201 has an important role in the pathogenesis of Alzheimer's disease with its three isoforms having disti
202 atment of clinical seizures in patients with Alzheimer's disease with select antiepileptic drugs (AED
203 N = 14), controls (N = 14) and "asymptomatic Alzheimer's disease" (ASYMAD), i.e., individuals with si
204 unity on neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, Park
205 unction leads to such disorders as epilepsy, Alzheimer's disease, and autism.
206 (Abeta) plays a crucial synaptotoxic role in Alzheimer's disease, and hyperphosphorylated tau facilit
207 he second most common form of dementia after Alzheimer's disease, and there is increasing awareness t
208 oid precursor protein (APP), a key player in Alzheimer's disease, belongs to the family of synaptic a
209 ds have a greater role for AMD compared with Alzheimer's disease, but a lesser role than for CAD.
210         Bryostatin is in clinical trials for Alzheimer's disease, cancer, and HIV/AIDS eradication.
211                                              Alzheimer's disease, dementia with Lewy bodies and genet
212 s, with known revised diagnosis in over 25% (Alzheimer's disease, dementia with Lewy bodies, and prog
213                             In patients with Alzheimer's disease, deposition of amyloid-beta is accom
214 k1A might be an ideal therapeutic target for Alzheimer's disease, especially for Down syndrome and EG
215 mation of amyloid beta fibrils implicated in Alzheimer's disease, gamma-secretase is an important tar
216 or protein, BACE1 is a therapeutic target in Alzheimer's disease, however, consistent with its role i
217  and PTEN dysregulation and suggest that, in Alzheimer's disease, impairment of brain insulin signali
218 ith an increased risk of dementia, including Alzheimer's disease, in patients with prostate cancer.
219 n are associated with the pathophysiology of Alzheimer's disease, it is clear that amyloid precursor
220 alogs for the management of type 2 diabetes, Alzheimer's disease, or other diseases related to IAPP d
221 hology in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington
222  such as anxiety, depression, schizophrenia, Alzheimer's disease, Parkinson's disease, and pain, prov
223 y of developing age-related diseases such as Alzheimer's disease, Parkinson's disease, multiple scler
224 litating protein deposition diseases such as Alzheimer's disease, prion diseases, and type II diabete
225 various neurodegenerative diseases including Alzheimer's disease, progressive supranuclear palsy and
226 ought to result in neurodegeneration causing Alzheimer's disease, progressive supranuclear palsy, chr
227 m antipsychotic prescribing for psychosis in Alzheimer's disease, the mechanisms underpinning antipsy
228  the brain increases with the progression of Alzheimer's disease, thus classifying BChE as a promisin
229 ker of neurodegenerative diseases, including Alzheimer's disease, where olfactory deficits precede de
230 erm memory performance and is reminiscent of Alzheimer's disease, which is characterized by degenerat
231 rformance in individuals at genetic risk for Alzheimer's disease, with the caveat that the order of c
232 -AD mouse brain slice culture model with key Alzheimer's disease-like changes.
233                                   Those with Alzheimer's disease-related cognitive impairment were yo
234 d BACE1 is accumulated in the distal axon of Alzheimer's disease-related mutant human APP transgenic
235         In this regard, new evidence linking Alzheimer's disease-related pathology and neuronal stem
236 pt of cognitive aging to include evidence of Alzheimer's disease-related protein aggregation as an un
237 ckness, suggesting that cortical thinning in Alzheimer's disease-vulnerable brain regions is a mechan
238 ic risk showed reduced cortical thickness in Alzheimer's disease-vulnerable regions.
239 eper understanding of the molecular basis of Alzheimer's disease.
240 autism spectrum disorder, schizophrenia, and Alzheimer's disease.
241 ergic hypofunction in patients with advanced Alzheimer's disease.
242 y amyloid-beta proteotoxic diseases, such as Alzheimer's disease.
243 n-specific manner to cognitive impairment in Alzheimer's disease.
244 esent a new therapeutic avenue for combating Alzheimer's disease.
245 led states is central to the pathogenesis of Alzheimer's disease.
246 degenerative neurological illnesses, such as Alzheimer's disease.
247 xic effect of Abeta(1-40) and Abeta(1-42) in Alzheimer's disease.
248 s the risk for the development of late-onset Alzheimer's disease.
249 cated in reducing the severity of stroke and Alzheimer's disease.
250  as autism spectrum disorder, depression and Alzheimer's disease.
251 ing TLR4-TLR6 dimerization as a treatment of Alzheimer's disease.
252  Ser367 should be useful in the treatment of Alzheimer's disease.
253 a with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
254 d individuals at early symptomatic stages of Alzheimer's disease.
255 ntribute to the loss of synaptic function in Alzheimer's disease.
256 umerous neuropsychiatric disorders including Alzheimer's disease.
257 t target for developing therapeutics against Alzheimer's disease.
258 e contributes directly to the development of Alzheimer's disease.
259 sion is associated with an increased risk of Alzheimer's disease.
260  plays a central role in the pathogenesis of Alzheimer's disease.
261 id and fcMRI in individuals with preclinical Alzheimer's disease.
262 ein 43 (TDP-43) is another protein linked to Alzheimer's disease.
263 regates in the brain tissue of patients with Alzheimer's disease.
264  higher in dementia with Lewy bodies than in Alzheimer's disease.
265 r of neural circuit defects in patients with Alzheimer's disease.
266 oup of community-dwelling veterans with mild Alzheimer's disease.
267 community-dwelling veterans (N=60) with mild Alzheimer's disease.
268 isk of side effects including angioedema and Alzheimer's disease.
269  BChE as a promising drug target in advanced Alzheimer's disease.
270 ggests a new link between RBFOX proteins and Alzheimer's disease.
271 treat psychosis, agitation and aggression in Alzheimer's disease.
272 loid fibrils is a defining characteristic of Alzheimer's disease.
273 hat are able to slow down the progression of Alzheimer's disease.
274 logical disorders, such as schizophrenia and Alzheimer's disease.
275 ousal and in pathological conditions such as Alzheimer's disease.
276 is, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease.
277 in other neurodegenerative disorders such as Alzheimer's disease.
278 ant for managing diseases such as cancer and Alzheimer's disease.
279 cluding multiple sclerosis (MS), stroke, and Alzheimer's disease.
280 nd aging and in models of brain ischemia and Alzheimer's disease.
281 on is an important modifiable risk factor in Alzheimer's disease.
282  well-known amyloid-beta peptide involved in Alzheimer's disease.
283 tiple neurodegenerative disorders, including Alzheimer's disease.
284 upancy for optimal treatment of psychosis in Alzheimer's disease.
285 suggesting a link between mRNA stability and Alzheimer's disease."
286              Herpes simplex virus type 1 and Alzheimer's disease: possible mechanisms and signposts.
287 is a dominant feature in the pathogenesis of Alzheimer's disease; however, it is not clear how indivi
288 eptic activity is frequently associated with Alzheimer's disease; this association has therapeutic im
289 re common disorders, such as Parkinson's and Alzheimer's diseases.
290 ritical to the neurodegenerative pathways of Alzheimer's, Huntington's, and Parkinson's diseases and
291 associated with degenerative diseases (i.e., Alzheimer's, Huntington's, and Parkinson's diseases), ca
292           NMNAT2 is significantly reduced in Alzheimer's, Huntington's, Parkinson's diseases.
293 Abeta) aggregation in vitro and suppress the Alzheimer's-like phenotypes in a transgenic mouse model
294 s in several neurodegenerative diseases like Alzheimer's, Parkinson's, prion diseases, etc.
295 s, the peptides and proteins associated with Alzheimer's, Parkinson's, type 2 diabetes and prion dise
296 s in episodic memory and the accumulation of Alzheimer's pathology are common in cognitively normal o
297 d 51% at age 80 years) or with suspected non-Alzheimer's pathophysiology (A-T+N-, A-T-N+, and A-T+N+;
298 usative factors underlying memory defects in Alzheimer's patients.
299  obtained from the International Genomics of Alzheimer's Project (17,008 AD cases and 37,154 controls
300  controls from the International Genomics of Alzheimer's Project (IGAP Stage 1), we identified AD-ass

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top